Dihexa has no completed human trials evaluating whether it improves cognition or causes harm in people. The molecule was developed by a university research group as an orally active analogue of angiotensin IV.
The Verdict
What Dihexa Has Actually Been Tested In
Published research on dihexa consists entirely of rodent experiments and cell-culture assays without any completed human clinical trials. The Harding and Wright academic group developed the molecule as an analogue of angiotensin IV. Every cognitive claim in the literature originates from animal tests.
Researchers assessed the substance in rodent maze tasks and isolated tissue preparations. These laboratory models measured synaptic markers and spatial navigation under controlled chemical conditions.
The molecule was previously nominated for compounding review before nominators withdrew it. Agency records show that dihexa acetate was later withdrawn from compounding nomination lists.
Federal reviewers found no records of human exposure. In official safety documents, regulators confirmed they lack necessary information to determine whether dihexa causes harm in humans. The compound remains an unapproved experimental chemical.
The Hepatocyte Growth Factor and c-Met Pathway
Dihexa acts biochemically through the hepatocyte growth factor and c-Met receptor system. A 2014 study reported that dihexa binds hepatocyte growth factor (HGF) with high affinity. The compound does not generate this signaling cascade on its own.
Researchers discovered that dihexa and its parent molecule, Norleucine-1-angiotensin IV, induce c-Met phosphorylation in the presence of subthreshold concentrations of HGF. It potentiates an existing biochemical signal. Without baseline HGF present, receptor activation did not occur.
The same published paper documented physical changes in cultured brain cells. Dihexa and Norleucine-1-angiotensin IV stimulated hippocampal spinogenesis and synaptogenesis resembling the actions of native HGF. Scientists confirmed this pathway using molecular inhibitors.
Applying an HGF antagonist completely halted new spine formation. Delivering a short hairpin RNA directed at c-Met also eliminated the structural response.
The mechanism was tested in live animals. When researchers administered dihexa orally to rodents, spatial learning improvements appeared in water maze trials. Infusing an HGF antagonist directly into rodent brain ventricles blocked this procognitive outcome.
What this establishes is a mechanism, not a clinical effect. The experiments confirm that the HGF and c-Met pathway is necessary for the compound to work in a rodent brain, and every one of them was run in rodents or in cells. The Food and Drug Administration states that it has identified no human exposure data for dihexa acetate at all, so a well-designed rodent mechanism is where the evidence stops. Readers tracking where these molecules sit federally can read our peptide therapy FDA status comparison.
What the Rodent Cognition Experiments Measured
Cognitive testing of dihexa relied on rodent memory impairment protocols rather than assessments of baseline healthy performance. Investigators frequently used scopolamine-induced spatial memory impairment. Scientific literature describes this setup as a generally accepted animal model for dementia-related memory dysfunction.
In an evaluation of metabolically stabilised angiotensin IV analogues, a 2 mg/kg oral dose of dihexa completely reversed the scopolamine-dependent learning deficit in that rodent model. This measured quantity represents an experimental animal dose.
It cannot be directly applied to human use. Investigators also evaluated the compound in genetic models.
A 2021 study evaluated dihexa in APP/PS1 transgenic mice, which serve as an animal model of Alzheimer's disease. The compound restored spatial learning in the Morris water maze. Authors linked these behavioral changes to activation of PI3K/AKT intracellular signalling cascades.
The Morris water maze is a standard rodent test of spatial learning. These animal maze results do not measure human reasoning, verbal memory, or general intelligence.
| Published Study | Experimental Model | Measured Outcome | Clinical Translation Boundary |
|---|---|---|---|
| 2014 HGF / c-Met Investigation | Cell cultures and rodents, with an HGF antagonist infused into the brain ventricles | c-Met phosphorylation, hippocampal spinogenesis, maze performance | Requires baseline HGF presence; animal and cell assays only |
| Angiotensin IV Analogue Study | Scopolamine-treated rodents | Reversal of induced learning deficit at 2 mg/kg oral rodent dose | Animal chemical impairment model; no human safety or dose data |
| 2021 Transgenic Mouse Study | APP/PS1 transgenic Alzheimer's mice | Restoration of spatial learning via PI3K/AKT signalling | Genetic rodent model; does not evaluate human dementia progression |
Federal Compounding Status and Regulatory Position
The Food and Drug Administration has approved no drug products containing dihexa for any medical indication. Federal compounding dockets clearly define its regulatory standing.
The FDA document titled Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks lists dihexa acetate under a specific classification. It appears under bulk drug substances nominated but withdrawn. These substances were previously in category 2 of interim compounding policies before their nominators withdrew them.
Agency reviewers stated that "FDA has not identified any human exposure data on drug products containing dihexa acetate administered via any route of administration." They added that "FDA lacks important information regarding any safety issues raised by dihexa acetate, including whether it would cause harm if administered to humans." These federal findings were current as of 22 April 2026.
Dihexa acetate currently appears on neither FDA bulks list. It does not sit in the active category 2 table. It is not on any list of substances permitted for compounding.
Other compounds occupy different positions in federal records. For contrast, molecules currently listed in the category 2 table include GHRP-6 and ipamorelin acetate, both placed there for 503B facilities on 29 September 2023. At Longevity Benchmark, we also publish an analysis of peptide therapy FDA status to see how other regulatory dockets compare.
| Substance Name | Current Compounding List Status | Regulatory Docket Action | Federal Review Finding |
|---|---|---|---|
| Dihexa acetate | Nominated but withdrawn | Removed from category 2 interim policy | Zero human exposure data identified by FDA |
Evaluating Nootropic and Cognitive Enhancement Claims
Marketing claims promoting dihexa as a potent nootropic extrapolate rodent maze outcomes to human cognitive performance. Online vendors frequently claim the molecule increases human intelligence. No clinical trials support this assertion.
The scientific record contains only rodent experiments and laboratory tissue preparations. Reversing scopolamine impairment in rats demonstrates chemical mitigation of an induced deficit. It does not demonstrate enhanced cognitive capacity in healthy animals or humans.
Claims that dihexa outperforms other research peptides are similarly untested in comparative human trials. No published study establishes a cognitive benefit in humans. Unverified claims should be viewed as untested hypotheses rather than established facts.
Consumers evaluating supplement purity and label transparency can read our guide on how to read a supplement label.
Evidence Required to Change the Clinical Picture
Changing this assessment would require completed human trial data. No such clinical evidence exists today.
Researchers would need to complete a controlled human trial. Such an investigation would need to evaluate a registered cognitive endpoint.
Those experiencing persistent memory changes or neurological symptoms should consult a licensed physician.
Readers can review clinical biomarkers and aging biology in our guide to what is biological age.
Frequently Asked Questions
Is dihexa FDA approved?
The Food and Drug Administration (FDA) has not approved dihexa for any human medical use or indication. There are no approved pharmaceutical drug products containing dihexa on the market. Furthermore, dihexa acetate does not appear on any list of substances permitted for compounding. In official compounding records, the agency categorized dihexa acetate under bulk drug substances nominated but later withdrawn by nominators. Regulators have stated that they lack safety data regarding whether the substance causes harm if administered to humans. Because no completed human trials exist, the compound remains an unapproved experimental chemical.
Does dihexa work?
Whether dihexa works depends entirely on the experimental model being evaluated. In published rodent studies, dihexa demonstrated measurable biological activity. A 2014 study showed that it binds hepatocyte growth factor with high affinity and stimulates c-Met phosphorylation in the presence of subthreshold HGF concentrations. In animal experiments using scopolamine-induced memory impairment and APP/PS1 transgenic mice, dihexa restored spatial learning in the Morris water maze. However, there are no completed human clinical trials evaluating its effects on human cognition, memory, or intelligence. Consequently, scientific evidence does not establish that dihexa works in human beings.
Is dihexa legal?
Dihexa's legal position is set by FDA's compounding lists rather than by any approval. There is no FDA-approved dihexa product. In federal compounding policy, dihexa acetate sits on the list of bulk drug substances nominated for compounding but withdrawn by nominators. As a result, it does not appear on FDA lists of bulk substances permitted for use in compounded medications. The regulatory records do not classify it as an approved therapeutic substance.
Is dihexa a peptide?
Dihexa is classified as a small-molecule analogue of angiotensin IV. It was developed by a university laboratory research group (the Harding and Wright group) rather than by a pharmaceutical company. Dihexa was synthesized as a metabolically stabilized, orally active compound that targets the hepatocyte growth factor and c-Met receptor system. While commonly referred to as a peptide in online communities, it is a small-molecule analogue of angiotensin IV.
Is dihexa a nootropic?
The classification of dihexa as a nootropic rests on published animal experiments rather than validated human clinical trials. Online communities and research chemical vendors label dihexa as a nootropic because of rodent trials using the Morris water maze. In those published studies, oral administration of the compound reversed learning deficits in rodents treated with scopolamine and improved spatial navigation in transgenic Alzheimer's mouse models. However, scientists have not established whether these rodent spatial memory improvements translate to human memory, focus, or cognitive performance. Because human clinical data is absent, its status as an effective human nootropic remains an unverified hypothesis.
Does dihexa increase intelligence?
There is no scientific evidence demonstrating that dihexa increases human intelligence. Published laboratory studies on the compound measured hippocampal spinogenesis in cell cultures and spatial navigation in rodents. A rodent maze assesses spatial learning under specific impairment conditions. It does not measure general intelligence, abstract logic, verbal reasoning, or executive cognitive function. Because no clinical trials have tested dihexa in humans, marketing claims asserting that the molecule increases human intelligence are entirely unsupported by empirical data.
Does dihexa increase BDNF?
The published scientific record for dihexa does not establish that the compound increases brain-derived neurotrophic factor (BDNF). Primary scientific literature on dihexa focuses on its actions through the hepatocyte growth factor (HGF) and c-Met receptor system. In published 2014 laboratory research, dihexa was shown to bind HGF with high affinity and induce c-Met phosphorylation in the presence of subthreshold HGF concentrations. The study demonstrated that blocking HGF or c-Met eliminated the compound's effects on dendritic spinogenesis and spatial learning. The peer-reviewed investigations defining dihexa's mechanism did not evaluate or measure changes in BDNF levels as an active outcome.
Is dihexa safe?
The safety profile of dihexa in humans is completely unknown because no clinical safety trials have ever been conducted. In official compounding evaluation records, the Food and Drug Administration (FDA) noted that it has identified no human exposure data for drug products containing dihexa acetate across any route of administration. The agency formally concluded that it lacks critical information regarding potential safety issues, including whether administering dihexa to humans would cause physical harm.